Late-stage disease treatment-focused AI-tech company Whiterabbit.ai has inked a national distribution agreement with San Francisco-based AI software powerhouse Arterys. Their directive is to proliferate Whiterabbit’s program for improving mammography screening compliance and volume, called ACT, on a nationwide scale. Leveraging millions of diversified data points, ACT has undergone testing in more than 300 breast cancer screening centers in the U.S. and shown a 20% year-over-year growth in overall breast cancer screening volume.
ACT will be made available to Arterys’ wide-ranging stable of healthcare systems, many of which already use its Breast AI software for breast cancer evaluation, measurement of breast density, and the creation of patient-specific risk assessment programs. The partners aim to chip away at the unfortunate glut of missed or overdue preventative screenings that have piled up over the course of the COVID-19 pandemic, which continues to keep patients away from physical clinics.
“Our strategic partnership with Arterys further anchors Whiterabbit’s mission to make late-stage diseases a rarity through increased accessibility, supported by innovative AI-powered software,” said Dr. Alexander Sardiña, Whiterabbit.ai’s Chief Executive Officer. “We believe AI has the power to transform healthcare through compliance, accurate disease detection, and a patient-centric approach at cost reduction.”